---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-116982"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2026-11-06T22:08:05+00:00"
generated_at: "2026-11-06T22:10:07.007350+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma raises ~$850K private placement at $1.50/share; net proceeds ~$815,000

## Summary
- Sold 136,005 common shares at $1.50 and pre-funded warrants for 430,661 shares at $1.4999, exercisable immediately at $0.0001 until fully exercised.
- Gross proceeds ~$850,000; net proceeds expected ~$815,000 after placement agent fees and offering expenses, earmarked for working capital and general corporate purposes.
- Purchasers capped at 4.99% beneficial ownership, adjustable to 9.99% on 61 days' prior notice to the Company.
- Registration Rights Agreement requires a resale registration statement filing within 30 days and effectiveness within 60 days (90 days if SEC conducts a full review).
- Silo obtained a right-of-first-refusal waiver from H.C. Wainwright for the offering; the placement closed November 6, 2026.

## SEC filing metadata
- accession: 0001213900-26-116982
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2026-11-06T22:08:05+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390026116982/0001213900-26-116982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390026116982/ea0311306-8k_silo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-116982
- JSON: https://secwatch.observer/filing/0001213900-26-116982.json
- Plain text: https://secwatch.observer/filing/0001213900-26-116982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.